



## REMARKS

Favorable opinion on the application as amended herein is earnestly solicited. The examiner is kindly invited to contact the undersigned by telephone to discuss matters which may further the prosecution of this application or facilitate the allowability of some or all of the claims herein.

Attached hereto is a marked-up version of the changes made to the specification and claims by the current amendment. The attached pages are captioned "Version with Markings to Show Changes Made".

Respectfully submitted,

---

Anthony J. Zelano (Reg. No. 27,969)  
Attorney for Applicant(s)

**MILLEN, WHITE, ZELANO & BRANIGAN, P.C.**  
Arlington Courthouse Plaza I  
2200 Clarendon Boulevard, Suite 1400  
Arlington, Virginia 22201  
Direct Dial: (703) 812-5311  
Facsimile No.: (703) 243-6410  
Internet Address: zelano@mwzb.com

**Filed: July 24, 2001**

AJZ/njr  
K:\Sch\1738\preliminar amendment 07.24.01.wpd



VERSION WITH MARKINGS TO SHOW CHANGES MADE

In the Claims:

Claims 3-10, 12-14 and 17-24 have been amended as follows:

3. Benzimidazoles according to claim 1 ~~or 2~~, wherein  
 $R^2$  means a monocyclic or bicyclic  $C_{6-10}$  aryl group or a monocyclic or bicyclic 5- to 10-membered heteroaryl group with 1-2 heteroatoms selected from the group that consists of N, S or O, whereby the mentioned aryl or heteroaryl group can be substituted with up to three of the following substituents, independently of one another:  
F, Cl, Br,  
XOH, XOR<sup>4</sup>, XOCOR<sup>4</sup>, XOCONHR<sup>4</sup>, XOCOOR<sup>4</sup>,  
XCOR<sup>4</sup>, XC(NOH)R<sup>4</sup>, XC(NOR<sup>4</sup>)R<sup>4</sup>, XC(NO(COR<sup>4</sup>))R<sup>4</sup>,  
XCOOH, XCOOR<sup>4</sup>, XCONH<sub>2</sub>, XCONHR<sup>4</sup>, XCONR<sup>4</sup>R<sup>4</sup>, XCONHOH,  
XCONHOR<sup>4</sup>, XCOSR<sup>4</sup>,  
XSR<sup>4</sup>, XSOR<sup>4</sup>, XSO<sub>2</sub>R<sup>4</sup>, SO<sub>2</sub>NH<sub>2</sub>, SO<sub>2</sub>NHR<sup>4</sup>, SO<sub>2</sub>NR<sup>4</sup>R<sup>4</sup>,  
NO<sub>2</sub>, XNHR<sup>4</sup>, XNR<sup>4</sup>R<sup>4</sup>, XNHSO<sub>2</sub>R<sup>4</sup>, XN(SO<sub>2</sub>R<sup>4</sup>)SO<sub>2</sub>R<sup>4</sup>, XNR<sup>4</sup>SO<sub>2</sub>R<sup>4</sup>, R<sup>4</sup>,  
whereby two substituents at  $R^2$ , if they are in ortho-position to one another, can be linked to one another in such a way that they jointly form methanediylbisoxy, ethane-1,2-diylbisoxy, propane-1,3-diyl, butane-1,4-diyl.
4. Benzimidazoles according to ~~one of claims 1-3~~ claim 1, wherein  
 $R^3$  means one or two substituents, which, independently of one another, can be:  
hydrogen, F, Cl, Br,  
XOH, XOR<sup>4</sup>, XOCOR<sup>4</sup>, XOCONHR<sup>4</sup>, XOCOOR<sup>4</sup>,  
XCOR<sup>4</sup>, XC(NOH)R<sup>4</sup>, XC(NOR<sup>4</sup>)R<sup>4</sup>, XC(NO(COR<sup>4</sup>))R<sup>4</sup>,  
XCN, XSR<sup>4</sup>, XSOR<sup>4</sup>, XSO<sub>2</sub>R<sup>4</sup>, SO<sub>2</sub>NH<sub>2</sub>, SO<sub>2</sub>NHR<sup>4</sup>, SO<sub>2</sub>NR<sup>4</sup>R<sup>4</sup>,  
NO<sub>2</sub>, XNH<sub>2</sub>, XNHR<sup>4</sup>, XNR<sup>4</sup>N<sup>4</sup>,  
XNHSO<sub>2</sub>R<sup>4</sup>, XNR<sup>4</sup>SO<sub>2</sub>R<sup>4</sup>, XN(SO<sub>2</sub>R<sup>4</sup>)SO<sub>2</sub>R<sup>4</sup>,

XNHCOR<sup>4</sup>, XNHCOOR<sup>4</sup>, XNHCONHR<sup>4</sup>, or R<sup>4</sup>, whereby two substituents R<sup>3</sup>, if they are in ortho-position to one another, can be linked to one another in such a way that they jointly form methanediylbisoxo, ethane-1,2-diylbisoxo, propane-1,3-diyl, or butane-1,4-diyl.

5. Benzimidazoles according to ~~one of claims 1-4~~ claim 1, wherein

R<sup>4</sup> and R<sup>4'</sup>, independently of one another, mean CF<sub>3</sub>, C<sub>2</sub>F<sub>5</sub>, C<sub>1-4</sub>

alkyl, C<sub>2-4</sub> alkenyl, C<sub>2-4</sub> alkynyl, C<sub>3-6</sub> cycloalkyl, (C<sub>1-3</sub> alkyl-C<sub>3-6</sub> cycloalkyl), phenyl or 5- to 6-membered heteroaryl with 1-2 N, S or O atoms, whereby the phenyl and heteroaryl groups can be substituted with one or two substituents from the group that consists of F, Cl, Br, CH<sub>3</sub>, C<sub>2</sub>H<sub>5</sub>, OCH<sub>3</sub>, OC<sub>2</sub>H<sub>5</sub>, CF<sub>3</sub>, C<sub>2</sub>F<sub>5</sub>,

and in addition in a 5-membered cycloalkyl ring, a ring

member can be an N or an O, and in a 6-membered cycloalkyl ring, one or two ring members can be N and/or O, whereby ring nitrogens optionally can be substituted with C<sub>1-3</sub> alkyl or C<sub>1-3</sub> alkanoyl.

6. Benzimidazoles according to ~~one of claims 1-5~~ claim 1, wherein

R<sup>5</sup> and R<sup>5'</sup>, independently of one another, can be C<sub>1-6</sub> alkyl,

whereby a carbon atom can be exchanged for O, NH, N C<sub>1-3</sub> alkyl, N C<sub>1-3</sub> alkanoyl,

C<sub>3-7</sub> cycloalkyl-C<sub>0-3</sub> alkyl, whereby in a 5-membered

cycloalkyl ring, a ring member can be an N or an O, and in a 6- or 7-

membered cycloalkyl ring, one or two ring members can be N and/or O,

whereby ring nitrogens optionally can be substituted with C<sub>1-3</sub> alkyl or C<sub>1-3</sub> alkanoyl, whereby the mentioned C<sub>1-6</sub> alkyl part can be substituted with one

of the previously mentioned cycloalkyls or else a 5- to 6-membered

heteroaromatic compound with 1-2 heteroatoms, selected from N, S or O,

whereby all previously mentioned alkyl and cycloalkyl parts can be

substituted with up to two substituents that consist of CF<sub>3</sub>, OH, O C<sub>1-3</sub> alkyl,

and the previously mentioned heteroaryl groups with one or two substituents

that consist of F, Cl, CF<sub>3</sub>, CH<sub>3</sub>, C<sub>2</sub>H<sub>5</sub>, OCH<sub>3</sub>, OC<sub>2</sub>H<sub>5</sub>, or R<sup>5</sup> and R<sup>5'</sup> together with the nitrogen atom form a 5- to 7-membered heterocyclic compound, which can contain another oxygen, nitrogen or sulfur atom and can be substituted with C<sub>1-4</sub> alkyl, C<sub>1-4</sub> alkoxy-C<sub>0-2</sub> alkyl, C<sub>1-4</sub> alkoxy-carbonyl, aminocarbonyl or phenyl.

7. Benzimidazoles according to ~~one of claims 1-6~~ claim 1, wherein  
**A** means C<sub>1-10</sub> alkanediyl, C<sub>2-10</sub> alkenediyl, C<sub>2-10</sub> alkinediyl, (C<sub>0-5</sub> alkanediyl-C<sub>3-7</sub> cycloalkanediyl-C<sub>0-5</sub> alkanediyl), whereby in a 5-membered cycloalkyl ring, a ring member can be an N or an O, or in a 6- or 7-membered cycloalkyl ring, one or two ring members can be N and/or O, whereby ring nitrogens optionally can be substituted with C<sub>1-3</sub> alkyl or C<sub>1-3</sub> alkanoyl, whereby in the above-mentioned aliphatic chains, a carbon atom or two carbon atoms can be exchanged for O, NH, N C<sub>1-3</sub> alkyl, or N C<sub>1-3</sub> alkanoyl.
8. Benzimidazoles according to ~~one of claims 1-7~~ claim 1, wherein  
**B** means COOH, COOR<sup>5</sup>, CONH<sub>2</sub>, CONHR<sup>5</sup>, CONR<sup>5</sup>R<sup>5'</sup>, CONHOH, CONHOR<sup>5</sup> or tetrazolyl,  
in each case bonded to a carbon atom of group A.
9. Benzimidazoles according to ~~one of claims 1-8~~ claim 1, wherein  
**X** means a bond or methylene.
10. Benzimidazoles according to ~~one of claims 1-9~~ claim 1, wherein  
**Y** means O.
12. 6-[[2-Phenyl-1-(3-pyridyl)-1H-benzimidazol-5-yl]oxy]hexanoic acid methyl ester  
6-[[2-phenyl-1-(3-pyridyl)-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester  
6-[[2-phenyl-1-(4-pyridyl)-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester  
6-[[2-(4-fluoro-phenyl)-1-phenyl-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester

ester

6-[[2-(4-methoxyphenyl)-1-phenyl-1H-benzimidazol-6-yl]oxy]-hexanoic acid methyl

ester

6-[[2-(4-bromophenyl)-1-phenyl-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl

ester

6-[[2-[4-(trifluoromethyl)phenyl]-1-phenyl-1H-benzimidazol-6-yl]oxy]hexanoic acid

methyl ester

6-[[1-phenyl-2-(benzothien-2-yl)-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl

ester

6-[[1-phenyl-2-(benzothien-2-yl)-1H-benzimidazol-6-yl]oxy]hexanoic acid

6-[[5-hydroxy-1-(4-methylphenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy]hexanoic

acid isopropyl ester

6-[[5-hydroxy-1-(4-methylphenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy]hexanoic

acid

6-[[5-methoxy-1-(4-methylphenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy]hexanoic

acid isopropyl ester

6-[[5-hydroxy-1-(4-methylphenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy]hexanoic

acid methyl ester

6-[[5-methoxy-1-(4-methylphenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy]hexanoic

acid methyl ester

6-[[5-[[4-(chlorophenyl)sulfonyl]amino]-1-(3,4-dimethylphenyl)-2-phenyl-1H-

benzimidazol-6-yl]oxy]hexanoic acid methyl ester benzimidazol-6-yl]oxy]hexanoic acid

methyl ester

6-[[5-[[4-(chlorophenyl)sulfonyl]amino]-2-(4-fluorophenyl)-1-(4-methoxyphenyl)-

1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester

6-[[5-[[4-(chlorophenyl)sulfonyl]amino]-1-(4-methoxyphenyl)-2-(4-methoxyphenyl)-

1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester

4-[[5-[[4-(chlorophenyl)sulfonyl]amino]-1-(4-methoxyphenyl)-2-phenyl-1H-

benzimidazol-6-yl]oxy]butanoic acid methyl ester

5-[[5-[[4-(chlorophenyl)sulfonyl]amino]-1-(4-methoxyphenyl)-2-phenyl-1H-

benzimidazol-6-yl]oxy]pentanoic acid methyl ester

5-[[5-[[4-(4-chlorophenyl)sulfonyl]amino]-1,2-diphenyl-1H-benzimidazol-6-yl]oxy]pentanoic acid methyl ester

6-[[5-[[4-(trifluoromethyl)phenyl)sulfonyl]amino]-1-(4-methoxyphenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester

6-[[5-[[4-(4-chlorophenyl)sulfonyl]methylamino]-1-(4-methoxyphenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester

6-[[1-(indan-5-yl)-2-phenyl-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester

6-[[1-(indan-5-yl)-2-phenyl-1H-benzimidazol-6-yl]oxy]hexanoic acid

6-[[1-(3-fluorophenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester

6-[[2-(4-nitrophenyl)-1-phenyl-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester

6-[[1-phenyl-2-(3-pyridinyl)-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester

N-(cyclopropylmethoxy)-6-[(1,2-diphenyl-1H-benzimidazol-6-yl)oxy]hexanamide

N-isobutoxy-6-[(1,2-diphenyl-1H-benzimidazol-6-yl)oxy]hexanamide

N-(cyclopropylmethoxy)-6-[2-phenyl-1-(3,4,5-trimethoxyphenyl)-1H-benzimidazol-6-yl]oxy]-hexanamide

N-isobutoxy-6-[2-phenyl-1-(3,4,5-trimethoxyphenyl)-1H-benzimidazol-6-yl]oxy]hexanamide

N-(2-methoxyethyl)-6-[(1,2-diphenyl-1H-benzimidazol-6-yl)oxy]hexanamide

N-(3-methoxypropyl)-6-[(1,2-diphenyl-1H-benzimidazol-6-yl)oxy]hexanamide

N-isobutyl-6-[(1,2-diphenyl-1H-benzimidazol-6-yl)oxy]hexanamide

6-[(1,2-diphenyl-1H-benzimidazol-6-yl)oxy]-1-morpholin-1-ylhexan-1-one

N,N-di(-2-methoxyethyl)-6-[(1,2-diphenyl-1H-benzimidazol-6-yl)oxy]hexanamide

N-isopentyl-6-[(1,2-diphenyl-1H-benzimidazol-6-yl)oxy]hexanamide

N-(pyridin-2-yl)-6-[(1,2-diphenyl-1H-benzimidazol-6-yl)oxy]hexanamide

N-(pyridin-3-yl)-6-[(1,2-diphenyl-1H-benzimidazol-6-yl)oxy]hexanamide

N-isopropyl-6-[[1-(3,4-dimethylphenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy]hexanamide

N,N-dimethyl-6-[[1-(3,4-dimethylphenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy]hexanamide

N,N-diethyl-6-[[1-(3,4-dimethylphenyl)-2-phenyl-1H-benzimidazol-6-

yl]oxy]hexanamide

N-isobutyl-6-[[1-(3,4-dimethylphenyl)-2-phenyl-1H-benzimidazol-6-

yl]oxy]hexanamide

N-cyclopropyl-6-[[1-(3,4-dimethylphenyl)-2-phenyl-1H-benzimidazol-6-

yl]oxy]hexanamide

N-cyclobutyl-6-[[1-(3,4-dimethylphenyl)-2-phenyl-1H-benzimidazol-6-

yl]oxy]hexanamide

N-tert-butyl-6-[[1-(3,4-dimethylphenyl)-2-phenyl-1H-benzimidazol-6-

yl]oxy]hexanamide

(R)-6-[[1-(3,4-dimethylphenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy]1-(2-methoxymethyl)-pyrrolidin-1-ylhexan-1-one

N-(3-imidazol-1-yl-propyl)-6-[[1-(3,4-dimethylphenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy]hexanamide

N-(2-pyridin-2-ylethyl)-6-[[1-(3,4-dimethylphenyl)-2-phenyl-1H-benzimidazol-6-yl]oxy]hexanamide

N-(3-methoxypropyl)-6-[[1-(indan-5-yl)-2-phenyl-1H-benzimidazol-6-yl]oxy]heptanamide

6-[[1-(4-methylphenyl)-2-(3-pyridyl)-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester

6-[[1-(4-methylphenyl)-2-(4-pyridyl)-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester

6-[[1-(4-methylphenyl)-2-(2-thienyl)-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester

6-[[1-(4-methylphenyl)-2-(3-thienyl)-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester

6-[[2-(3-indolyl)-1-(4-methylphenyl)-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester

6-[[1-(4-methylphenyl)-2-(2-furyl)-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester

6-[[1-(4-methylphenyl)-2-(3-furyl)-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester

6-[[1-(4-methylphenyl)-2-(5-methyl-2-thienyl)-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester

6-[[1-(4-methylphenyl)-2-(3-methyl-2-thienyl)-1H-benzimidazol-6-yl]oxy]hexanoic acid methyl ester, -

each a compound of claim 1.

13. Use of a compound according to ~~one of claims 1-12~~ claim 1 for the production of a pharmaceutical agent for treating or preventing diseases that are associated with a microglia activation.

14. Pharmaceutical agent, wherein it contains one or more compounds according to ~~one of claims 1-12~~ claim 1 and one or more vehicles.

17. Use according to claim 15 ~~or 16~~, whereby in general formula II,

$R^2$  means a monocyclic or bicyclic aryl group or a monocyclic or bicyclic 5- to 10-membered heteroaryl group with 1-2 heteroatoms selected from the group that consists of N, S or O, whereby the mentioned aryl group or heteroaryl group can be substituted with up to three of the following substituents, independently of one another:

F, Cl, Br, XOH, XOR<sup>4</sup>, XOCOR<sup>4</sup>, XOCONHR<sup>4</sup>, XOCOOR<sup>4</sup>,

XCOR<sup>4</sup>, XC(NO<sup>4</sup>)R<sup>4</sup>,

XC(NOR<sup>4</sup>)R<sup>4</sup>, XC(NO(COR<sup>4</sup>))R<sup>4</sup>, XCN, XCOOH, XCOOR<sup>4</sup>, XCONH<sub>2</sub>,

XCONR<sup>4</sup>R<sup>4</sup>,

XCONHR<sup>4</sup>, XCONHOH, XCONHOR<sup>4</sup>, XCOSR<sup>4</sup>, XSR<sup>4</sup>, XSOR<sup>4</sup>, XSO<sub>2</sub>R<sup>4</sup>,

SO<sub>2</sub>NH<sub>2</sub>, SO<sub>2</sub>NHR<sup>4</sup>, SO<sub>2</sub>NR<sup>4</sup>R<sup>4</sup>, NO<sub>2</sub>, XNH<sub>2</sub>, XNHR<sup>4</sup>, XNR<sup>4</sup>R<sup>4</sup>,

XNH<sub>2</sub>SO<sub>2</sub>R<sup>4</sup>,

XN(SO<sub>2</sub>R<sup>4</sup>)(SO<sub>2</sub>R<sup>4</sup>), XNR<sup>4</sup>SO<sub>2</sub>R<sup>4</sup>, XNHCOR<sup>4</sup>, XNHCOOR<sup>4</sup>,

XNHCONHR<sup>4</sup>, R<sup>4</sup>,



whereby two substituents at  $R^2$ , if they are in ortho-position to one another, can be linked to one another in such a way that they jointly form methanediylbisoxy, ethane-1,2-diylbisoxy, propane-1,3-diyl, butane-1,4-diyl.

18. Use according to ~~claims 15-17~~ claim 15, whereby in general formula II  $R^3$  stands for one or two substituents, which independently of one another, mean:

hydrogen,

F, Cl, Br, XOH,  $XOR^4$ ,  $XOCOR^4$ ,  $XOCONHR^4$ ,

$XOCOOR^4$ ,  $XCOR^4$ ,  $XC(NOHR^4)$ ,  $XC(NOR^4)R^4$ ,  $XC(NO(COR^4))R^4$ ,

$XCN$ ,  $XSR^4$ ,  $XSOR^4$ ,  $XSO_2R^4$ ,  $SO_2NH_2$ ,  $SO_2NHR^4$ ,  $SO_2NR^4R^4$ ,  $NO_2$ ,

$XNH_2$ ,  $XNHR^4$ ,  $XNR^4R^4$ ,  $XNHSO_2R^4$ ,  $XNR^4SO_2R^4$ ,  $XN(SO_2R^4)(SO_2R^4)$ ,

$XNHCOR^4$ ,  $XNHCOOR^4$ ,  $XNHCONHR^4$ , or  $R^4$ , whereby two substituents  $R^3$ , if they are in ortho-position to one another, can be linked to one another in such a way that they jointly form methanediylbisoxy, ethane-1,2-diylbisoxy, propane-1,3-diyl, butane-1,4-diyl.

19. Use according to ~~claims 15-18~~ claim 15, whereby in general formula II

$R^4$  and  $R^4$ , independently of one another, mean  $CF_3$ ,  $C_2F_5$ ,  $C_{1-4}$

alkyl,  $C_{2-4}$  alkenyl,  $C_{2-4}$  alkynyl,  $C_{3-6}$  cycloalkyl, ( $C_{1-3}$  alkyl- $C_{3-6}$  cycloalkyl),

$C_{1-3}$  alkylaryl,  $C_{1-3}$  alkylheteroaryl, monocyclic aryl or 5- to 6-membered

heteroaryl with 1-2 N, S or O atoms, whereby the aryl and heteroaryl groups

can be substituted with one or two substituents from the group that consists

of F, Cl, Br,  $CH_3$ ,  $C_2H_5$ ,  $NO_2$ ,  $OCH_3$ ,  $OC_2H_5$ ,  $CF_3$ ,  $C_2F_5$  or else can carry

an annelated methanediylbisoxy or ethane-1,2-diylbisoxy group, and in

addition in a 5-membered cycloalkyl ring, a ring member can be an N or an

O, and in a 6-membered cycloalkyl ring, one or two ring members can be N

and/or O, whereby ring nitrogens optionally can be substituted with  $C_{1-3}$

alkyl or  $C_{1-3}$  alkanoyl.

20. Use according to ~~claims 15-19~~ claim 15, whereby in general formula II  $R^5$  and  $R^{5'}$ , independently of one another, can be  $C_{1-6}$  alkyl,

whereby a carbon atom can be exchanged for O, NH, N  $C_{1-3}$  alkyl, N  $C_{1-3}$  alkanoyl,  $C_{3-7}$  cycloalkyl- $C_{0-3}$  alkyl, whereby in a 5-membered cycloalkyl ring, a ring member can be an N or an O, and in a 6- or 7-membered cycloalkyl ring, one or two ring members can be N and/or O, whereby ring nitrogens optionally can be substituted with  $C_{1-3}$  alkyl or  $C_{1-3}$  alkanoyl, whereby the mentioned  $C_{1-6}$  alkyl part can be substituted with one of the previously mentioned cycloalkyls or else a 5- to 6-membered heteroaromatic compound with 1-2 heteroatoms, selected from the group that consists of N, S or O,

whereby all previously mentioned alkyl and cycloalkyl parts can be substituted with up to two substituents that consist of  $CF_3$ , OH, O  $C_{1-3}$  alkyl, and the previously mentioned heteroaryl groups can be substituted with one or two substituents that consist of F, Cl,  $CF_3$ ,  $CH_3$ ,  $C_2H_5$ ,  $OCH_3$ ,  $OC_2H_5$ , or  $R^5$  and  $R^{5'}$  together with the nitrogen atom form a 5- to 7-membered heterocyclic compound, which can contain another oxygen, nitrogen or sulfur atom and can be substituted with  $C_{1-4}$  alkyl,  $C_{1-4}$  alkoxy- $C_{0-2}$  alkyl,  $C_{1-4}$  alkoxy-carbonyl, aminocarbonyl or phenyl.

21. Use according to ~~claims 15-20~~ claim 15, whereby in general formula II

A means  $C_{1-10}$  alkanediyl,  $C_{2-10}$  alkenediyl,  $C_{2-10}$  alkinediyl, ( $C_{0-5}$  alkanediyl- $C_{3-7}$  cycloalkanediyl- $C_{0-5}$  alkanediyl), or ( $C_{0-5}$  alkanediyl-heteroarylene- $C_{0-5}$  alkanediyl), whereby an optionally present heteroaryl group can be substituted with one or two substituents that consist of F, Cl, Br,  $CH_3$ ,  $C_2H_5$ ,  $NO_2$ ,  $OCH_3$ ,  $OC_2H_5$ ,  $CF_3$ ,  $C_2F_5$ , and in addition in a 5-membered cycloalkyl ring, a ring member can be an N or an O, and in a 6- or 7-membered cycloalkyl ring, one or two ring members can be N and/or O, whereby ring nitrogens optionally can be substituted with  $C_{1-3}$  alkyl or  $C_{1-3}$  alkanoyl, whereby in an aliphatic chain, a carbon atom or two carbon atoms can be exchanged for O, NH, N  $C_{1-3}$  alkyl, N  $C_{1-3}$  alkanoyl,  $NSO_2$   $C_{1-3}$  alkyl,

and whereby alkyl or cycloalkyl parts can be substituted with up to two F atoms or one of the substituents that consists of OH, O C<sub>1-3</sub> alkyl, O C<sub>1-3</sub> alkanoyl, =O, NH<sub>2</sub>, NH C<sub>1-3</sub> alkyl, N (C<sub>1-3</sub> alkyl)<sub>2</sub>, NH C<sub>1-3</sub> alkanoyl, N (C<sub>1-3</sub> alkyl) (C<sub>1-3</sub> alkanoyl), NHCOO C<sub>1-3</sub> alkyl, NHCONH C<sub>1-3</sub> alkyl, NHSO<sub>2</sub> C<sub>1-3</sub> alkyl, SH, S C<sub>1-3</sub> alkyl.

22. Use according to ~~claims 15-21~~ claim 15, whereby in general formula II  
**B** means hydrogen, OH, OCOR<sup>5</sup>, OCONHR<sup>5</sup>, OCOOR<sup>5</sup>, COOH, COOR<sup>5</sup>, CONH<sub>2</sub>, CONHR<sup>5</sup>, CONR<sup>5</sup>R<sup>5'</sup>, CONHOH, CONHOR<sup>5</sup>, or tetrazolyl, in each case bonded to a carbon atom of group A.
23. Use according to ~~claims 15-22~~ claim 15, whereby in general formula II,  
**X** means a bond or CH<sub>2</sub>.
24. Use according to ~~claims 15-23~~ claim 15, whereby in general formula II,  
**Y** means a bond, O, S, NH, NR<sup>4</sup>, NCOR<sup>4</sup> or NSO<sub>2</sub>R<sup>4</sup>.